ClinicalTrials.gg
CompletedNCT02387762Updated Apr 2, 2019Results posted

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

A Phase 2 interventional study of acalabrutinib and Placebo in Rheumatoid Arthritis, sponsored by Acerta Pharma BV. Completed at 17 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-04-02.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Arthritis, Rheumatoid by AstraZeneca — 4 open to participants now, 4 under way, none of them phase 3. Arthritis, Rheumatoid · AstraZeneca.

Enrollment
31st of 45
31 · median 72
Started
2015
with 1 other
Phase 2
16 of 49
1 open now
Registered
40th of 49
by date

Among the 49 studies in Arthritis, Rheumatoid by AstraZeneca, this one is the 31st largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2015, is one of 16 in phase 2, and was the 40th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 49 studies in Arthritis, Rheumatoid by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Arthritis, Rheumatoid by AstraZeneca, or all of them as a file.
02

Study summary

This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background Methotrexate.

Read the detailed description

A multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. The on-treatment period is 4 weeks with weekly visits to the clinic, followed by a 4-week safety follow-up period after the last dose of ACP-196/placebo. The study was to evaluate the safety, PK, PD, and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background Methotrexate

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Acalabrutinib
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Diagnosis of RA according to the 2010 ACR/EULAR Classification Criteria .
  • Must be on a stable MTX dose (7.5 to 25 mg/week)
  • Subjects must be able to read and understand the consent form, complete the study-related procedures, and communicate with the study staff.
  • Are willing and able to adhere to the study visit schedule, and understand and comply with other protocol requirements.

Main Exclusion Criteria:

  • Prior , except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 5 years.
  • A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ACP-196, or put the study outcomes at undue risk.
  • Subjects who have taken any drug within the previous 30 days before randomization.
  • Use of all other synthetic disease-modifying antirheumatic drugs (DMARDS) such as but not limited to leflunomide, azathioprine, cyclosporine, penicillamine or gold salts within 8 weeks of randomization.
  • Use of etanercept, anakinra, tofacitinib within 4 weeks of randomization.
  • Use of abatacept, humira, infliximab, or tocilizumab within 8 weeks of randomization.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    ACP-196 + Methotrexate

    Oral acalabrutinib 15 mg QD plus a stable dose of methotrexate (MTX) between 7.5 mg and 25 mg per week

    Drug: acalabrutinib

  • Placebo comparator
    Placebo + Methotrexate

    Oral placebo QD plus a stable dose of MTX between 7.5 mg and 25 mg per week

    Drug: Placebo

Interventions

  • Also known as: methotrexate

  • DrugPlacebo

    Also known as: methotrexate

06

What researchers measure

Primary outcomes

  1. Disease Activity Score 28-CRP (DAS28-CRP) at Week 4

    Disease activity score 28 - C-reactive protein (DAS28-CRP) is a score to measure disease activity in patients with rheumatoid arthritis by aggregating data of 28 joints, and is calculated by the scores on scale using the following variables: The number of swollen and tender joints, CRP level, and patient's global assessment of disease activity. The total score of the DAS28 values may range from 2.0 to 10.0 while higher values mean a higher disease activity.

    Time frame: 4 weeks

07

Results

Posted Mar 26, 2019

Participant flow

Participant flow — Overall Study
MilestoneACP-196 + MethotrexatePlacebo + Methotrexate
Started1615
Completed1515
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryDisease Activity Score 28-CRP (DAS28-CRP) at Week 4

Disease activity score 28 - C-reactive protein (DAS28-CRP) is a score to measure disease activity in patients with rheumatoid arthritis by aggregating data of 28 joints, and is calculated by the scores on scale using the following variables: The number of swollen and tender joints, CRP level, and patient's global assessment of disease activity. The total score of the DAS28 values may range from 2.0 to 10.0 while higher values mean a higher disease activity.

Time frame:
4 weeks
Reported as:
Mean · Scores on scale
Disease Activity Score 28-CRP (DAS28-CRP) at Week 4
Scores on scaleACP 196 + MethotrexatePlacebo + Methotrexate
Disease Activity Score 28-CRP (DAS28-CRP) at Week 45.40 ± 1.5635.05 ± 1.639

Adverse events

Collected over From the date of the first dose of study drug up to 30 days after the date of the last dose of study drug, up to 6 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ACP-196 + Methotrexate0/16 (0%)0/16 (0%)10/16 (62.5%)
Placebo + Methotrexate0/15 (0%)0/15 (0%)6/15 (40%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventACP-196 + MethotrexatePlacebo + Methotrexate
AnaemiaBlood and lymphatic system disorders2/160/15
DiarrheaGastrointestinal disorders1/161/15
NauseaGastrointestinal disorders1/161/15
Oedema peripheralGeneral disorders1/161/15
Clavicle fractureInjury, poisoning and procedural complications0/161/15
FallInjury, poisoning and procedural complications0/161/15
Hip FractureInjury, poisoning and procedural complications0/161/15
Blood uric acid increasedInvestigations0/161/15
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/161/15
LethargyNervous system disorders0/161/15

Baseline characteristics

Intent-to-treat population, which included all randomized subjects

Age, Categorical
Age, Categorical(Participants)ACP-196 + MethotrexatePlacebo + MethotrexateTotal
<=18 years000
Between 18 and 65 years101222
>=65 years639
Age, Continuous
Age, Continuous(years)ACP-196 + MethotrexatePlacebo + MethotrexateTotal
Mean61.3 ± 7.2156.8 ± 7.9259.1 ± 7.78
Sex: Female, Male
Sex: Female, Male(Participants)ACP-196 + MethotrexatePlacebo + MethotrexateTotal
Female141327
Male224
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ACP-196 + MethotrexatePlacebo + MethotrexateTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander011
Black or African American235
White141024
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)ACP-196 + MethotrexatePlacebo + MethotrexateTotal
United States161531
DAS28-CRP at baseline
DAS28-CRP at baseline(Scores on Scale)ACP-196 + MethotrexatePlacebo + MethotrexateTotal
Mean6.29 ± 1.2426.29 ± 1.2206.29 ± 1.211
Duration of rheumatoid arthritis since initial diagnosis
Duration of rheumatoid arthritis since initial diagnosis(years)ACP-196 + MethotrexatePlacebo + MethotrexateTotal
Mean10.3 ± 7.527.8 ± 8.129.1 ± 7.78
Methotrexate dosing at baseline
Methotrexate dosing at baseline(mg/week)ACP-196 + MethotrexatePlacebo + MethotrexateTotal
Mean16.9 ± 6.4917.7 ± 5.2217.3 ± 5.82
08

Study locations

17 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • Achieve Clinical Research
    Birmingham, Alabama 35216, United States
  • Advanced Arthritis Care and Research
    Scottsdale, Arizona 85258, United States
  • TriWest Research Associates, LLC
    El Cajon, California 92020, United States
  • Neuropsychiatric Research Center of Orange County
    Orange, California 92868, United States
  • Pacific Arthritis Center Medical Group
    Santa Monica, California 93454, United States
  • Inland Rheumatology and Osteoporosis Medical Group, Inc
    Upland, California 91786, United States
  • San Marcus Research Clinic, Inc.
    Hialeah, Florida 33015, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • The Arthritis Center
    Palm Harbor, Florida 34684-3176, United States
  • Office of George Timothy Kelly, MD
    Las Vegas, Nevada 89128, United States
  • PMG Research of Salisbury
    Salisbury, North Carolina 28144, United States
  • Health Research of Oklahoma
    Oklahoma City, Oklahoma 73103-2433, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Ramesh C. Gupta, MD
    Memphis, Tennessee 38119, United States
  • Clear Lake Regional Medical Center
    Webster, Texas 77598, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of May 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2019, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2015
First posted
Mar 13, 2015
Start
Apr 2015
Primary completionActual
May 2016
CompletionActual
Jun 2016
Results first posted
Mar 26, 2019
Last update
Apr 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02387762
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Mar 13, 2015
Start date
Apr 2015
Primary completion
May 2016
Completion
Jun 2016
Results posted
Mar 26, 2019
Last update
Apr 2, 2019

Study contacts

Acerta Clinical Trials
study director · Acerta Pharma, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion